Next Article in Journal / Special Issue
Genetic Substrate Reduction Therapy: A Promising Approach for Lysosomal Storage Disorders
Previous Article in Journal / Special Issue
Mitochondrial Dysfunction in Lysosomal Storage Disorders
Article Menu

Export Article

Open AccessReview
Diseases 2016, 4(4), 32; doi:10.3390/diseases4040032

Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases

Department of Biochemistry and Molecular Genetics, Gregory Fleming Cystic Fibrosis Research Center, Comprehensive Arthritis, Musculoskeletal, Bone, and Autoimmunity Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA
Academic Editors: Jose A. Sanchez-Alcazar and Luis M. Jiménez
Received: 30 August 2016 / Revised: 13 October 2016 / Accepted: 14 October 2016 / Published: 19 October 2016
(This article belongs to the Collection Lysosomal Storage Diseases)
View Full-Text   |   Download PDF [1080 KB, uploaded 20 October 2016]   |  

Abstract

In-frame premature termination codons (PTCs) (also referred to as nonsense mutations) comprise ~10% of all disease-associated gene lesions. PTCs reduce gene expression in two ways. First, PTCs prematurely terminate translation of an mRNA, leading to the production of a truncated polypeptide that often lacks normal function and/or is unstable. Second, PTCs trigger degradation of an mRNA by activating nonsense-mediated mRNA decay (NMD), a cellular pathway that recognizes and degrades mRNAs containing a PTC. Thus, translation termination and NMD are putative therapeutic targets for the development of treatments for genetic diseases caused by PTCs. Over the past decade, significant progress has been made in the identification of compounds with the ability to suppress translation termination of PTCs (also referred to as readthrough). More recently, NMD inhibitors have also been explored as a way to enhance the efficiency of PTC suppression. Due to their relatively low threshold for correction, lysosomal storage diseases are a particularly relevant group of diseases to investigate the feasibility of nonsense suppression as a therapeutic approach. In this review, the current status of PTC suppression and NMD inhibition as potential treatments for lysosomal storage diseases will be discussed. View Full-Text
Keywords: lysosomal storage diseases; nonsense mutation; suppression; premature termination codon; readthrough; nonsense-mediated mRNA decay; translation termination; therapy; treatment lysosomal storage diseases; nonsense mutation; suppression; premature termination codon; readthrough; nonsense-mediated mRNA decay; translation termination; therapy; treatment
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Keeling, K.M. Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases. Diseases 2016, 4, 32.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top